{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T21:48:00Z","timestamp":1782164880467,"version":"3.54.5"},"reference-count":163,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11030-024-11093-3","type":"journal-article","created":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T04:30:11Z","timestamp":1738557011000},"page":"5185-5217","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Thiazolidinedione derivatives: emerging role in cancer therapy"],"prefix":"10.1007","volume":"29","author":[{"given":"Ganesh","family":"Latambale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kapil","family":"Juvale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,3]]},"reference":[{"key":"11093_CR1","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1158\/1055-9965.EPI-15-0578","volume":"25","author":"LA Torre","year":"2016","unstructured":"Torre LA, Siegel RL, Ward EM, Jemal A (2016) Global cancer incidence and mortality rates and trends\u2013an update. Cancer Epidemiol Biomarkers Prev 25:16\u201327. https:\/\/doi.org\/10.1158\/1055-9965.EPI-15-0578","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"11093_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clinicians 74:229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA A Cancer J Clinicians"},{"key":"11093_CR3","first-page":"1","volume-title":"Paclitaxel","author":"MS Chandraprasad","year":"2022","unstructured":"Chandraprasad MS, Dey A, Swamy MK (2022) 1 - Introduction to cancer and treatment approaches. In: Swamy MK, Pullaiah T, Chen Z-S (eds) Paclitaxel. Academic Press, pp 1\u201327"},{"key":"11093_CR4","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2012.ed16","author":"S Chakraborty","year":"2012","unstructured":"Chakraborty S, Rahman T (2012) The difficulties in cancer treatment. ecancer. https:\/\/doi.org\/10.3332\/ecancer.2012.ed16","journal-title":"ecancer"},{"key":"11093_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/slct.202401216","volume":"9","author":"R Pal","year":"2024","unstructured":"Pal R, Kumaraswamy B, Md. Ashadul SK, et al (2024) Advancement of DDR1 and DDR2 inhibitors: therapeutic potential of bioactive compounds, designing strategies, and structure-activity relationship (SAR). ChemistrySelect 9:e202401216. https:\/\/doi.org\/10.1002\/slct.202401216","journal-title":"ChemistrySelect"},{"key":"11093_CR6","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1080\/17415990500322792","volume":"26","author":"MVND Souza","year":"2006","unstructured":"Souza MVND (2006) Synthesis and biological activity of natural thiazoles: An important class of heterocyclic compounds. J Sulfur Chem 26:429\u2013449. https:\/\/doi.org\/10.1080\/17415990500322792","journal-title":"J Sulfur Chem"},{"key":"11093_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2023.136021","volume":"1291","author":"R Pal","year":"2023","unstructured":"Pal R, Teli G, Matada GSP, Dhiwar PS (2023) Designing strategies, structural activity relationship and biological activity of recently developed nitrogen containing heterocyclic compounds as epidermal growth factor receptor tyrosinase inhibitors. J Mol Struct 1291:136021. https:\/\/doi.org\/10.1016\/j.molstruc.2023.136021","journal-title":"J Mol Struct"},{"key":"11093_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2024.107696","volume":"152","author":"R Pal","year":"2024","unstructured":"Pal R, Matada GSP, Teli G et al (2024) Therapeutic potential of anticancer activity of nitrogen-containing heterocyclic scaffolds as Janus kinase (JAK) inhibitor: Biological activity, selectivity, and structure\u2013activity relationship. Bioorg Chem 152:107696. https:\/\/doi.org\/10.1016\/j.bioorg.2024.107696","journal-title":"Bioorg Chem"},{"key":"11093_CR9","doi-asserted-by":"publisher","first-page":"4338","DOI":"10.2174\/0929867323666160809093930","volume":"23","author":"D Kumar","year":"2016","unstructured":"Kumar D, Kumar Jain S (2016) A comprehensive review of N-heterocycles as cytotoxic agents. Curr Med Chem 23:4338\u20134394. https:\/\/doi.org\/10.2174\/0929867323666160809093930","journal-title":"Curr Med Chem"},{"key":"11093_CR10","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3390\/ph16020299","volume":"16","author":"A Kumar","year":"2023","unstructured":"Kumar A, Singh AK, Singh H et al (2023) Nitrogen containing heterocycles as anticancer agents: a medicinal chemistry perspective. Pharmaceuticals 16:299. https:\/\/doi.org\/10.3390\/ph16020299","journal-title":"Pharmaceuticals"},{"key":"11093_CR11","doi-asserted-by":"publisher","first-page":"8117","DOI":"10.3390\/ijms23158117","volume":"23","author":"O Ebenezer","year":"2022","unstructured":"Ebenezer O, Jordaan MA, Carena G et al (2022) An overview of the biological evaluation of selected nitrogen-containing heterocycle medicinal chemistry compounds. Int J Mol Sci 23:8117. https:\/\/doi.org\/10.3390\/ijms23158117","journal-title":"Int J Mol Sci"},{"key":"11093_CR12","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1021\/cr960010b","volume":"97","author":"A Nefzi","year":"1997","unstructured":"Nefzi A, Ostresh JM, Houghten RA (1997) The current status of heterocyclic combinatorial libraries. Chem Rev 97:449\u2013472. https:\/\/doi.org\/10.1021\/cr960010b","journal-title":"Chem Rev"},{"key":"11093_CR13","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/J.JARE.2020.01.008","volume":"23","author":"G Bansal","year":"2020","unstructured":"Bansal G, Thanikachalam PV, Maurya RK et al (2020) An overview on medicinal perspective of thiazolidine-2,4-dione: A remarkable scaffold in the treatment of type 2 diabetes. J Adv Res 23:163. https:\/\/doi.org\/10.1016\/J.JARE.2020.01.008","journal-title":"J Adv Res"},{"key":"11093_CR14","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S1367-5931(97)80015-4","volume":"1","author":"TM Willson","year":"1997","unstructured":"Willson TM, Wahli W (1997) Peroxisome proliferator-activated receptor agonists. Curr Opin Chem Biol 1:235\u2013241. https:\/\/doi.org\/10.1016\/S1367-5931(97)80015-4","journal-title":"Curr Opin Chem Biol"},{"key":"11093_CR15","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.bmcl.2004.12.041","volume":"15","author":"D Gupta","year":"2005","unstructured":"Gupta D, Ghosh NN, Chandra R (2005) Synthesis and pharmacological evaluation of substituted 5-[4-[2-(6,7-dimethyl-1,2,3,4-tetrahydro-2-oxo-4-quinoxalinyl)ethoxy]phenyl]methylene]thiazolidine-2,4-dione derivatives as potent euglycemic and hypolipidemic agents. Bioorg Med Chem Lett 15:1019\u20131022. https:\/\/doi.org\/10.1016\/j.bmcl.2004.12.041","journal-title":"Bioorg Med Chem Lett"},{"key":"11093_CR16","unstructured":"Eggleton JS, Jialal I (2024) Thiazolidinediones. In: StatPearls. StatPearls Publishing, Treasure Island (FL). Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK551656\/"},{"key":"11093_CR17","doi-asserted-by":"publisher","first-page":"4539","DOI":"10.1016\/J.EJMECH.2010.07.014","volume":"45","author":"V Patil","year":"2010","unstructured":"Patil V, Tilekar K, Mehendale-Munj S et al (2010) Synthesis and primary cytotoxicity evaluation of new 5-benzylidene-2,4-thiazolidinedione derivatives. Eur J Med Chem 45:4539\u20134544. https:\/\/doi.org\/10.1016\/J.EJMECH.2010.07.014","journal-title":"Eur J Med Chem"},{"key":"11093_CR18","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/ARDP.200500180","volume":"339","author":"M Tuncbilek","year":"2006","unstructured":"Tuncbilek M, Altanlar N (2006) Synthesis of New 3-(Substituted Phenacyl)-5-[3\u2032-(4H\u20134-oxo-1-benzopyran-2-yl)-benzylidene]-2,4-thiazolidinediones and their Antimicrobial Activity. Arch Pharm 339:213\u2013216. https:\/\/doi.org\/10.1002\/ARDP.200500180","journal-title":"Arch Pharm"},{"key":"11093_CR19","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/J.BBALIP.2007.04.016","volume":"1771","author":"MT Heneka","year":"2007","unstructured":"Heneka MT, Landreth GE (2007) PPARs in the brain. Biochem Biophys Acta 1771:1031\u20131045. https:\/\/doi.org\/10.1016\/J.BBALIP.2007.04.016","journal-title":"Biochem Biophys Acta"},{"key":"11093_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/S40199-014-0086-1","author":"RS Bahare","year":"2015","unstructured":"Bahare RS, Ganguly S, Choowongkomon K, Seetaha S (2015) Synthesis, HIV-1 RT inhibitory, antibacterial, antifungal and binding mode studies of some novel N-substituted 5-benzylidine-2,4-thiazolidinediones. DARU J Pharm Sci. https:\/\/doi.org\/10.1186\/S40199-014-0086-1","journal-title":"DARU J Pharm Sci"},{"key":"11093_CR21","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.1016\/s0960-894x(98)00485-5","volume":"8","author":"C Prabhakar","year":"1998","unstructured":"Prabhakar C, Madhusudhan G, Sahadev K et al (1998) Synthesis and biological activity of novel thiazolidinediones. Bioorg Med Chem Lett 8:2725\u20132730. https:\/\/doi.org\/10.1016\/s0960-894x(98)00485-5","journal-title":"Bioorg Med Chem Lett"},{"key":"11093_CR22","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1016\/j.bmcl.2009.03.026","volume":"19","author":"N Sunduru","year":"2009","unstructured":"Sunduru N, Srivastava K, Rajakumar S et al (2009) Synthesis of novel thiourea, thiazolidinedione and thioparabanic acid derivatives of 4-aminoquinoline as potent antimalarials. Bioorg Med Chem Lett 19:2570\u20132573. https:\/\/doi.org\/10.1016\/j.bmcl.2009.03.026","journal-title":"Bioorg Med Chem Lett"},{"key":"11093_CR23","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1016\/j.bmc.2005.02.026","volume":"13","author":"R Maccari","year":"2005","unstructured":"Maccari R, Ottan\u00e0 R, Curinga C et al (2005) Structure-activity relationships and molecular modelling of 5-arylidene-2,4-thiazolidinediones active as aldose reductase inhibitors. Bioorg Med Chem 13:2809\u20132823. https:\/\/doi.org\/10.1016\/j.bmc.2005.02.026","journal-title":"Bioorg Med Chem"},{"key":"11093_CR24","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.ejmech.2013.10.005","volume":"70","author":"Y Chinthala","year":"2013","unstructured":"Chinthala Y, Kumar Domatti A, Sarfaraz A et al (2013) Synthesis, biological evaluation and molecular modeling studies of some novel thiazolidinediones with triazole ring. Eur J Med Chem 70:308\u2013314. https:\/\/doi.org\/10.1016\/j.ejmech.2013.10.005","journal-title":"Eur J Med Chem"},{"key":"11093_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/BF02980237","author":"JG Hyo","year":"2007","unstructured":"Hyo JG, Kang BM, Jeon R (2007) Synthesis and biological activity of 5-(4-[2-(Methyl-p-substituted phenylamino)ethoxy]benzyl)thiazolidine-2,4-diones. Arch Pharm Res. https:\/\/doi.org\/10.1007\/BF02980237","journal-title":"Arch Pharm Res"},{"key":"11093_CR26","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/J.EJMECH.2012.01.019","volume":"49","author":"YM Ha","year":"2012","unstructured":"Ha YM, Park YJ, Kim JA et al (2012) Design and synthesis of 5-(substituted benzylidene)thiazolidine-2,4-dione derivatives as novel tyrosinase inhibitors. Eur J Med Chem 49:245\u2013252. https:\/\/doi.org\/10.1016\/J.EJMECH.2012.01.019","journal-title":"Eur J Med Chem"},{"key":"11093_CR27","doi-asserted-by":"publisher","first-page":"6161","DOI":"10.1016\/J.BMCL.2009.09.020","volume":"19","author":"BR Bhattarai","year":"2009","unstructured":"Bhattarai BR, Kafle B, Hwang JS et al (2009) Thiazolidinedione derivatives as PTP1B inhibitors with antihyperglycemic and antiobesity effects. Bioorg Med Chem Lett 19:6161\u20136165. https:\/\/doi.org\/10.1016\/J.BMCL.2009.09.020","journal-title":"Bioorg Med Chem Lett"},{"key":"11093_CR28","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/845340","author":"E Fr\u00f6hlich","year":"2015","unstructured":"Fr\u00f6hlich E, Wahl R (2015) Chemotherapy and chemoprevention by thiazolidinediones. BioMed Res Int. https:\/\/doi.org\/10.1155\/2015\/845340","journal-title":"BioMed Res Int"},{"key":"11093_CR29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-62703-420-3","volume-title":"Peroxisome proliferator-activated receptors: Discovery and recent advances","author":"JA Youssef","year":"2013","unstructured":"Youssef JA, Badr MZ (2013) Peroxisome proliferator-activated receptors: Discovery and recent advances. Humana Press, Totowa, pp 1\u2013137"},{"key":"11093_CR30","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1345\/APH.1R754","volume":"47","author":"RL Koffarnus","year":"2013","unstructured":"Koffarnus RL, Wargo KA, Phillippe HM (2013) Rivoglitazone: a new thiazolidinedione for the treatment of type 2 diabetes mellitus. Ann Pharmacother 47:877\u2013885. https:\/\/doi.org\/10.1345\/APH.1R754","journal-title":"Ann Pharmacother"},{"key":"11093_CR31","doi-asserted-by":"publisher","first-page":"4143","DOI":"10.1016\/J.BMCL.2009.05.126","volume":"19","author":"HN Hafez","year":"2009","unstructured":"Hafez HN, El-Gazzar ARBA (2009) Synthesis and antitumor activity of substituted triazolo[4,3-a]pyrimidin-6-sulfonamide with an incorporated thiazolidinone moiety. Bioorg Med Chem Lett 19:4143\u20134147. https:\/\/doi.org\/10.1016\/J.BMCL.2009.05.126","journal-title":"Bioorg Med Chem Lett"},{"key":"11093_CR32","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1016\/j.bmcl.2004.02.087","volume":"14","author":"Y-H Fan","year":"2004","unstructured":"Fan Y-H, Chen H, Natarajan A et al (2004) Structure-activity requirements for the antiproliferative effect of troglitazone derivatives mediated by depletion of intracellular calcium. Bioorg Med Chem Lett 14:2547\u20132550. https:\/\/doi.org\/10.1016\/j.bmcl.2004.02.087","journal-title":"Bioorg Med Chem Lett"},{"key":"11093_CR33","doi-asserted-by":"publisher","first-page":"3977","DOI":"10.1021\/jm00049a017","volume":"37","author":"BC Cantello","year":"1994","unstructured":"Cantello BC, Cawthorne MA, Cottam GP et al (1994) [[omega-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents. J Med Chem 37:3977\u20133985. https:\/\/doi.org\/10.1021\/jm00049a017","journal-title":"J Med Chem"},{"key":"11093_CR34","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1016\/J.BMC.2010.01.021","volume":"18","author":"AM Youssef","year":"2010","unstructured":"Youssef AM, White MS, Villanueva EB et al (2010) Synthesis and biological evaluation of novel pyrazolyl-2,4-thiazolidinediones as anti-inflammatory and neuroprotective agents. Bioorg Med Chem 18:2019\u20132028. https:\/\/doi.org\/10.1016\/J.BMC.2010.01.021","journal-title":"Bioorg Med Chem"},{"key":"11093_CR35","doi-asserted-by":"publisher","first-page":"3886","DOI":"10.1210\/jc.2004-1267","volume":"90","author":"MJ Betz","year":"2005","unstructured":"Betz MJ, Shapiro I, Fassnacht M et al (2005) Peroxisome proliferator-activated receptor-\u03b3 agonists suppress adrenocortical tumor cell proliferation and induce differentiation. J Clin Endocrinol Metab 90:3886\u20133896. https:\/\/doi.org\/10.1210\/jc.2004-1267","journal-title":"J Clin Endocrinol Metab"},{"key":"11093_CR36","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/J.BMC.2005.08.043","volume":"14","author":"GR Madhavan","year":"2005","unstructured":"Madhavan GR, Chakrabarti R, Reddy KA et al (2005) Dual PPAR-alpha and -gamma activators derived from novel benzoxazinone containing thiazolidinediones having antidiabetic and hypolipidemic potential. Bioorg Med Chem 14:584\u2013591. https:\/\/doi.org\/10.1016\/J.BMC.2005.08.043","journal-title":"Bioorg Med Chem"},{"key":"11093_CR37","doi-asserted-by":"publisher","first-page":"6042","DOI":"10.1016\/J.BMCL.2009.09.057","volume":"19","author":"Q Li","year":"2009","unstructured":"Li Q, Al-Ayoubi A, Guo T et al (2009) Structure-activity relationship (SAR) studies of 3-(2-amino-ethyl)-5-(4-ethoxy-benzylidene)-thiazolidine-2,4-dione: development of potential substrate-specific ERK1\/2 inhibitors. Bioorg Med Chem Lett 19:6042\u20136046. https:\/\/doi.org\/10.1016\/J.BMCL.2009.09.057","journal-title":"Bioorg Med Chem Lett"},{"key":"11093_CR38","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/nri2748","volume":"10","author":"CK Glass","year":"2010","unstructured":"Glass CK, Saijo K (2010) Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells. Nat Rev Immunol 10:365\u2013376. https:\/\/doi.org\/10.1038\/nri2748","journal-title":"Nat Rev Immunol"},{"key":"11093_CR39","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.3390\/ijms23031464","volume":"23","author":"X Wen","year":"2022","unstructured":"Wen X, Jiao L, Tan H (2022) MAPK\/ERK pathway as a central regulator in vertebrate organ regeneration. Int J Mol Sci 23:1464. https:\/\/doi.org\/10.3390\/ijms23031464","journal-title":"Int J Mol Sci"},{"key":"11093_CR40","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1111\/j.1742-4658.2009.07514.x","volume":"277","author":"Y Xiao","year":"2010","unstructured":"Xiao Y, Yuan T, Yao W, Liao K (2010) 3T3-L1 adipocyte apoptosis induced by thiazolidinediones is peroxisome proliferator-activated receptor-\u03b3-dependent and mediated by the caspase-3-dependent apoptotic pathway. FEBS J 277:687\u2013696. https:\/\/doi.org\/10.1111\/j.1742-4658.2009.07514.x","journal-title":"FEBS J"},{"key":"11093_CR41","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ctrv.2005.12.006","volume":"32","author":"T Liu","year":"2006","unstructured":"Liu T, Kuljaca S, Tee A, Marshall GM (2006) Histone deacetylase inhibitors: Multifunctional anticancer agents. Cancer Treat Rev 32:157\u2013165. https:\/\/doi.org\/10.1016\/j.ctrv.2005.12.006","journal-title":"Cancer Treat Rev"},{"key":"11093_CR42","first-page":"25","volume":"6","author":"C Blanquicett","year":"2008","unstructured":"Blanquicett C, Roman J, Hart CM (2008) Thiazolidinediones as anti-cancer agents. Cancer Ther 6:25","journal-title":"Cancer Ther"},{"key":"11093_CR43","doi-asserted-by":"publisher","first-page":"5436","DOI":"10.3390\/ijms21155436","volume":"21","author":"P-K Wu","year":"2020","unstructured":"Wu P-K, Becker A, Park J-I (2020) Growth inhibitory signaling of the Raf\/MEK\/ERK pathway. Int J Mol Sci 21:5436. https:\/\/doi.org\/10.3390\/ijms21155436","journal-title":"Int J Mol Sci"},{"key":"11093_CR44","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3892\/ijmm.2018.3936","volume":"43","author":"Q Wang","year":"2019","unstructured":"Wang Q, Lu D, Fan L et al (2019) COX-2 induces apoptosis-resistance in hepatocellular carcinoma cells via the HIF-1\u03b1\/PKM2 pathway. Int J Mol Med 43:475\u2013488. https:\/\/doi.org\/10.3892\/ijmm.2018.3936","journal-title":"Int J Mol Med"},{"key":"11093_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2017.00031","author":"V Vella","year":"2017","unstructured":"Vella V, Nicolosi ML, Giuliano S et al (2017) PPAR-\u03b3 agonists as antineoplastic agents in cancers with dysregulated IGF axis. Front Endocrinol. https:\/\/doi.org\/10.3389\/fendo.2017.00031","journal-title":"Front Endocrinol"},{"key":"11093_CR46","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","volume":"6","author":"M Konopleva","year":"2016","unstructured":"Konopleva M, Pollyea DA, Potluri J et al (2016) Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous Leukemia. Cancer Discov 6:1106\u20131117. https:\/\/doi.org\/10.1158\/2159-8290.CD-16-0313","journal-title":"Cancer Discov"},{"key":"11093_CR47","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1517\/13543784.2014.884708","volume":"23","author":"H Joshi","year":"2014","unstructured":"Joshi H, Pal T, Ramaa C (2014) A new dawn for the use of thiazolidinediones in cancer therapy. Expert Opin Investig Drugs 23:501\u2013510. https:\/\/doi.org\/10.1517\/13543784.2014.884708","journal-title":"Expert Opin Investig Drugs"},{"key":"11093_CR48","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s43046-022-00110-x","volume":"34","author":"P Malakouti","year":"2022","unstructured":"Malakouti P, Mohammadi M, Boshagh MA et al (2022) Combined effects of pioglitazone and doxorubicin on migration and invasion of MDA-MB-231 breast cancer cells. J Egypt Natl Canc Inst 34:13. https:\/\/doi.org\/10.1186\/s43046-022-00110-x","journal-title":"J Egypt Natl Canc Inst"},{"key":"11093_CR49","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.fct.2012.09.006","volume":"51","author":"MF Mahmoud","year":"2013","unstructured":"Mahmoud MF, El Shazly SM (2013) Pioglitazone protects against cisplatin induced nephrotoxicity in rats and potentiates its anticancer activity against human renal adenocarcinoma cell lines. Food Chem Toxicol 51:114\u2013122. https:\/\/doi.org\/10.1016\/j.fct.2012.09.006","journal-title":"Food Chem Toxicol"},{"key":"11093_CR50","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/1471-2407-9-107","volume":"9","author":"K Tikoo","year":"2009","unstructured":"Tikoo K, Kumar P, Gupta J (2009) Rosiglitazone synergizes anticancer activity of cisplatin and reduces its nephrotoxicity in 7, 12-dimethyl benz{a}anthracene (DMBA) induced breast cancer rats. BMC Cancer 9:107. https:\/\/doi.org\/10.1186\/1471-2407-9-107","journal-title":"BMC Cancer"},{"key":"11093_CR51","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2010.877","author":"Mansour,","year":"2011","unstructured":"Mansour, (2011) Thiazolidinediones\/PPAR\u00ce3 agonists and fatty acid synthase inhibitors as an experimental combination therapy for prostate cancer. Int J Oncol. https:\/\/doi.org\/10.3892\/ijo.2010.877","journal-title":"Int J Oncol"},{"key":"11093_CR52","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1248\/bpb.21.547","volume":"21","author":"M Rbisawa","year":"1998","unstructured":"Rbisawa M, Kawachi E, Fukasawa H et al (1998) Novel thiazolidinedione derivatives with retinoid synergistic activity. Biol Pharm Bull 21:547\u2013549. https:\/\/doi.org\/10.1248\/bpb.21.547","journal-title":"Biol Pharm Bull"},{"key":"11093_CR53","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1186\/1471-2407-12-410","volume":"12","author":"PJ Mazzone","year":"2012","unstructured":"Mazzone PJ, Rai H, Beukemann M et al (2012) The effect of metformin and thiazolidinedione use on lung cancer in diabetics. BMC Cancer 12:410. https:\/\/doi.org\/10.1186\/1471-2407-12-410","journal-title":"BMC Cancer"},{"key":"11093_CR54","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1093\/annonc\/mdr020","volume":"22","author":"X-X He","year":"2011","unstructured":"He X-X, Tu SM, Lee M-H, Yeung S-CJ (2011) Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients. Ann Oncol 22:2640\u20132645. https:\/\/doi.org\/10.1093\/annonc\/mdr020","journal-title":"Ann Oncol"},{"key":"11093_CR55","doi-asserted-by":"publisher","first-page":"13661","DOI":"10.3390\/ijms241713661","volume":"24","author":"E Burgermeister","year":"2023","unstructured":"Burgermeister E (2023) Mitogen-activated protein kinase and nuclear hormone receptor crosstalk in cancer immunotherapy. Int J Mol Sci 24:13661. https:\/\/doi.org\/10.3390\/ijms241713661","journal-title":"Int J Mol Sci"},{"key":"11093_CR56","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.18632\/oncotarget.6626","volume":"7","author":"C-H Tseng","year":"2015","unstructured":"Tseng C-H (2015) Metformin may reduce oral cancer risk in patients with type 2 diabetes. Oncotarget 7:2000\u20132008. https:\/\/doi.org\/10.18632\/oncotarget.6626","journal-title":"Oncotarget"},{"key":"11093_CR57","doi-asserted-by":"publisher","first-page":"197","DOI":"10.2174\/1568009619666191209102015","volume":"20","author":"P Mrowka","year":"2020","unstructured":"Mrowka P, Glodkowska-Mrowka E (2020) PPAR\u03b3 agonists in combination cancer therapies. Curr Cancer Drug Targets 20:197\u2013215. https:\/\/doi.org\/10.2174\/1568009619666191209102015","journal-title":"Curr Cancer Drug Targets"},{"key":"11093_CR58","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1002\/cmdc.202100177","volume":"16","author":"N Long","year":"2021","unstructured":"Long N, Le Gresley A, Wren SP (2021) Thiazolidinediones: An in\u2013depth study of their synthesis and application to medicinal chemistry in the treatment of diabetes mellitus. ChemMedChem 16:1717\u20131736. https:\/\/doi.org\/10.1002\/cmdc.202100177","journal-title":"ChemMedChem"},{"key":"11093_CR59","doi-asserted-by":"publisher","first-page":"2953","DOI":"10.1016\/j.bmc.2015.03.071","volume":"23","author":"N Chadha","year":"2015","unstructured":"Chadha N, Bahia MS, Kaur M, Silakari O (2015) Thiazolidine-2,4-dione derivatives: Programmed chemical weapons for key protein targets of various pathological conditions. Bioorg Med Chem 23:2953\u20132974. https:\/\/doi.org\/10.1016\/j.bmc.2015.03.071","journal-title":"Bioorg Med Chem"},{"key":"11093_CR60","doi-asserted-by":"publisher","first-page":"182","DOI":"10.3390\/compounds2030013","volume":"2","author":"F Damkaci","year":"2022","unstructured":"Damkaci F, Szymaniak AA, Biasini JP, Cotroneo R (2022) Synthesis of thiazolidinedione compound library. Compounds 2:182\u2013190. https:\/\/doi.org\/10.3390\/compounds2030013","journal-title":"Compounds"},{"key":"11093_CR61","doi-asserted-by":"publisher","DOI":"10.7717\/PEERJ.5386\/SUPP-2","author":"DM Corigliano","year":"2018","unstructured":"Corigliano DM, Syed R, Messineo S et al (2018) Indole and 2,4-Thiazolidinedione conjugates as potential anticancer modulators. PeerJ.https:\/\/doi.org\/10.7717\/PEERJ.5386\/SUPP-2","journal-title":"PeerJ"},{"key":"11093_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/J.MOLSTRUC.2021.131767","volume":"1250","author":"K Tilekar","year":"2022","unstructured":"Tilekar K, Shelke O, Upadhyay N et al (2022) Current status and future prospects of molecular hybrids with thiazolidinedione (TZD) scaffold in anticancer drug discovery. J Mol Struct 1250:131767. https:\/\/doi.org\/10.1016\/J.MOLSTRUC.2021.131767","journal-title":"J Mol Struct"},{"key":"11093_CR63","doi-asserted-by":"publisher","first-page":"4817","DOI":"10.4067\/S0717-97072020000204817","volume":"65","author":"DMR Rashid","year":"2020","unstructured":"Rashid DMR, Asif DAH, Neelima DNS (2020) synthesis and SAR strategy of thiazolidinedione: a novel approach for cancer treatment. J Chil Chem Soc 65:4817\u20134832. https:\/\/doi.org\/10.4067\/S0717-97072020000204817","journal-title":"J Chil Chem Soc"},{"key":"11093_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12935-021-02202-5","volume":"21","author":"A Olatunde","year":"2021","unstructured":"Olatunde A, Nigam M, Singh RK et al (2021) Cancer and diabetes: the interlinking metabolic pathways and repurposing actions of antidiabetic drugs. Cancer Cell Int 21:1\u201327. https:\/\/doi.org\/10.1186\/S12935-021-02202-5","journal-title":"Cancer Cell Int"},{"key":"11093_CR65","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1517\/13543784.12.12.1925","volume":"12","author":"D Panigrahy","year":"2003","unstructured":"Panigrahy D, Shen LQ, Kieran MW, Kaipainen A (2003) Therapeutic potential of thiazolidinediones as anticancer agents. Expert Opin Investig Drugs 12:1925\u20131937. https:\/\/doi.org\/10.1517\/13543784.12.12.1925","journal-title":"Expert Opin Investig Drugs"},{"key":"11093_CR66","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/BIOMEDICINES10010024\/S1","volume":"10","author":"MY Sameeh","year":"2022","unstructured":"Sameeh MY, Khowdiary MM, Nassar HS et al (2022) Discovery potent of thiazolidinedione derivatives as antioxidant, \u03b1-amylase inhibitor, and antidiabetic agent. Biomedicines 10:24. https:\/\/doi.org\/10.3390\/BIOMEDICINES10010024\/S1","journal-title":"Biomedicines"},{"key":"11093_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/J.EJMECH.2024.116139","volume":"266","author":"G Singh","year":"2024","unstructured":"Singh G, Singh R, Monga V, Mehan S (2024) 3,5-Disubstituted-thiazolidine-2,4-dione hybrids as antidiabetic agents: Design, synthesis, in-vitro and In vivo evaluation. Eur J Med Chem 266:116139. https:\/\/doi.org\/10.1016\/J.EJMECH.2024.116139","journal-title":"Eur J Med Chem"},{"key":"11093_CR68","doi-asserted-by":"publisher","first-page":"5599","DOI":"10.1021\/acs.jmedchem.7b00282","volume":"60","author":"T-K Yeh","year":"2017","unstructured":"Yeh T-K, Kuo C-C, Lee Y-Z et al (2017) Design, synthesis, and evaluation of thiazolidine-2,4-dione derivatives as a novel class of glutaminase inhibitors. J Med Chem 60:5599\u20135612. https:\/\/doi.org\/10.1021\/acs.jmedchem.7b00282","journal-title":"J Med Chem"},{"key":"11093_CR69","doi-asserted-by":"publisher","first-page":"13135","DOI":"10.3390\/ijms232113135","volume":"23","author":"P Roszczenko","year":"2022","unstructured":"Roszczenko P, Holota S, Szewczyk OK et al (2022) 4-Thiazolidinone-bearing hybrid molecules in anticancer drug design. Int J Mol Sci 23:13135. https:\/\/doi.org\/10.3390\/ijms232113135","journal-title":"Int J Mol Sci"},{"key":"11093_CR70","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1056\/NEJMra043590","volume":"353","author":"AI Shulman","year":"2005","unstructured":"Shulman AI, Mangelsdorf DJ (2005) Retinoid x receptor heterodimers in the metabolic syndrome. N Engl J Med 353:604\u2013615. https:\/\/doi.org\/10.1056\/NEJMra043590","journal-title":"N Engl J Med"},{"key":"11093_CR71","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.bbalip.2007.03.006","volume":"1771","author":"S Heikkinen","year":"2007","unstructured":"Heikkinen S, Auwerx J, Argmann CA (2007) PPAR\u03b3 in human and mouse physiology. Biochim Biophys Acta Mol Cell Biol Lipids 1771:999\u20131013. https:\/\/doi.org\/10.1016\/j.bbalip.2007.03.006","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"11093_CR72","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/250126","volume":"2010","author":"N Viswakarma","year":"2010","unstructured":"Viswakarma N, Jia Y, Bai L et al (2010) Coactivators in PPAR-regulated gene expression. PPAR Res 2010:250126. https:\/\/doi.org\/10.1155\/2010\/250126","journal-title":"PPAR Res"},{"key":"11093_CR73","doi-asserted-by":"publisher","first-page":"1069718","DOI":"10.1155\/2017\/1069718","volume":"2017","author":"N Thangavel","year":"2017","unstructured":"Thangavel N, Bratty MA, Javed SA et al (2017) Targeting peroxisome proliferator-activated receptors using thiazolidinediones: strategy for design of novel antidiabetic drugs. Int J Med Chem 2017:1069718. https:\/\/doi.org\/10.1155\/2017\/1069718","journal-title":"Int J Med Chem"},{"key":"11093_CR74","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1002\/JCP.20738","volume":"209","author":"M Li","year":"2006","unstructured":"Li M, Lee TW, Yim APC et al (2006) Apoptosis induced by troglitazone is both peroxisome proliferator-activated receptor-gamma- and ERK-dependent in human non-small lung cancer cells. J Cell Physiol 209:428\u2013438. https:\/\/doi.org\/10.1002\/JCP.20738","journal-title":"J Cell Physiol"},{"key":"11093_CR75","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1677\/ERC.1.01182","volume":"13","author":"JR Weng","year":"2006","unstructured":"Weng JR, Chen CY, Pinzone JJ et al (2006) Beyond peroxisome proliferator-activated receptor gamma signaling: the multi-facets of the antitumor effect of thiazolidinediones. Endocr Relat Cancer 13:401\u2013413. https:\/\/doi.org\/10.1677\/ERC.1.01182","journal-title":"Endocr Relat Cancer"},{"key":"11093_CR76","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1023\/A:1016114026769","volume":"74","author":"E Elstner","year":"2002","unstructured":"Elstner E, Williamson EA, Zang C et al (2002) Novel therapeutic approach: ligands for PPARgamma and retinoid receptors induce apoptosis in bcl-2-positive human breast cancer cells. Breast Cancer Res Treat 74:155\u2013165. https:\/\/doi.org\/10.1023\/A:1016114026769","journal-title":"Breast Cancer Res Treat"},{"key":"11093_CR77","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1593\/neo.04601","volume":"7","author":"VG Keshamouni","year":"2005","unstructured":"Keshamouni VG, Arenberg DA, Reddy RC et al (2005) PPAR-\u03b3 activation inhibits angiogenesis by blocking ELR+CXC chemokine production in non-small cell lung cancer. Neoplasia 7:294\u2013301. https:\/\/doi.org\/10.1593\/neo.04601","journal-title":"Neoplasia"},{"key":"11093_CR78","doi-asserted-by":"publisher","first-page":"13503","DOI":"10.1074\/jbc.M510357200","volume":"281","author":"KY Kim","year":"2006","unstructured":"Kim KY, Cheon HG (2006) Antiangiogenic effect of rosiglitazone is mediated via peroxisome proliferator-activated receptor \u03b3-activated maxi-k channel opening in human umbilical vein endothelial cells *. J Biol Chem 281:13503\u201313512. https:\/\/doi.org\/10.1074\/jbc.M510357200","journal-title":"J Biol Chem"},{"key":"11093_CR79","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s10456-005-9027-4","volume":"8","author":"LLH Peeters","year":"2006","unstructured":"Peeters LLH, Vigne J-L, Tee MK et al (2006) PPAR $$\\upgamma$$ represses VEGF expression in human endometrial cells: Implications for uterine angiogenesis. Angiogenesis 8:373\u2013379. https:\/\/doi.org\/10.1007\/s10456-005-9027-4","journal-title":"Angiogenesis"},{"key":"11093_CR80","doi-asserted-by":"publisher","first-page":"4072","DOI":"10.1021\/jm0510880","volume":"49","author":"AG Chittiboyina","year":"2006","unstructured":"Chittiboyina AG, Venkatraman MS, Mizuno CS et al (2006) Design and synthesis of the first generation of dithiolane thiazolidinedione- and phenylacetic acid-based PPAR\u03b3 agonists. J Med Chem 49:4072\u20134084. https:\/\/doi.org\/10.1021\/jm0510880","journal-title":"J Med Chem"},{"key":"11093_CR81","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3390\/ph15020226","volume":"15","author":"MA Abdelgawad","year":"2022","unstructured":"Abdelgawad MA, El-Adl K, El-Hddad SSA et al (2022) Design, molecular docking, synthesis, anticancer and anti-hyperglycemic assessments of thiazolidine-2,4-diones bearing sulfonylthiourea moieties as potent VEGFR-2 inhibitors and PPAR\u03b3 agonists. Pharmaceuticals 15:226. https:\/\/doi.org\/10.3390\/ph15020226","journal-title":"Pharmaceuticals"},{"key":"11093_CR82","doi-asserted-by":"publisher","first-page":"6442","DOI":"10.1016\/j.bmcl.2012.08.052","volume":"22","author":"VR Avupati","year":"2012","unstructured":"Avupati VR, Yejella RP, Akula A et al (2012) Synthesis, characterization and biological evaluation of some novel 2,4-thiazolidinediones as potential cytotoxic, antimicrobial and antihyperglycemic agents. Bioorg Med Chem Lett 22:6442\u20136450. https:\/\/doi.org\/10.1016\/j.bmcl.2012.08.052","journal-title":"Bioorg Med Chem Lett"},{"key":"11093_CR83","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/nrc2109","volume":"7","author":"S Schubbert","year":"2007","unstructured":"Schubbert S, Shannon K, Bollag G (2007) Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 7:295\u2013308. https:\/\/doi.org\/10.1038\/nrc2109","journal-title":"Nat Rev Cancer"},{"key":"11093_CR84","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1038\/sj.onc.1210422","volume":"26","author":"PJ Roberts","year":"2007","unstructured":"Roberts PJ, Der CJ (2007) Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26:3291\u20133310. https:\/\/doi.org\/10.1038\/sj.onc.1210422","journal-title":"Oncogene"},{"key":"11093_CR85","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1038\/leu.2008.26","volume":"22","author":"LS Steelman","year":"2008","unstructured":"Steelman LS, Abrams SL, Whelan J et al (2008) Contributions of the Raf\/MEK\/ERK, PI3K\/PTEN\/Akt\/mTOR and Jak\/STAT pathways to leukemia. Leukemia 22:686\u2013707. https:\/\/doi.org\/10.1038\/leu.2008.26","journal-title":"Leukemia"},{"key":"11093_CR86","doi-asserted-by":"publisher","first-page":"14477","DOI":"10.1073\/pnas.0606836103","volume":"103","author":"H Gao","year":"2006","unstructured":"Gao H, Ouyang X, Banach-Petrosky WA et al (2006) Combinatorial activities of Akt and B-Raf\/Erk signaling in a mouse model of androgen-independent prostate cancer. Proc Natl Acad Sci U S A 103:14477\u201314482. https:\/\/doi.org\/10.1073\/pnas.0606836103","journal-title":"Proc Natl Acad Sci U S A"},{"key":"11093_CR87","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1172\/JCI34764","volume":"118","author":"CW Kinkade","year":"2008","unstructured":"Kinkade CW, Castillo-Martin M, Puzio-Kuter A et al (2008) Targeting AKT\/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest 118:3051\u20133064. https:\/\/doi.org\/10.1172\/JCI34764","journal-title":"J Clin Invest"},{"key":"11093_CR88","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.4161\/cc.9.9.11483","volume":"9","author":"SL Abrams","year":"2010","unstructured":"Abrams SL, Steelman LS, Shelton JG et al (2010) The Raf\/MEK\/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy. Cell Cycle 9:1781\u20131791. https:\/\/doi.org\/10.4161\/cc.9.9.11483","journal-title":"Cell Cycle"},{"key":"11093_CR89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-023-01705-z","volume":"8","author":"ME Bahar","year":"2023","unstructured":"Bahar ME, Kim HJ, Kim DR (2023) Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: from mechanism to clinical studies. Sig Transduct Target Ther 8:1\u201338. https:\/\/doi.org\/10.1038\/s41392-023-01705-z","journal-title":"Sig Transduct Target Ther"},{"key":"11093_CR90","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ejmech.2011.10.031","volume":"47","author":"K Liu","year":"2012","unstructured":"Liu K, Rao W, Parikh H et al (2012) 3,5-Disubstituted-thiazolidine-2,4-dione analogs as anticancer agents: Design, synthesis and biological characterization. Eur J Med Chem 47:125\u2013137. https:\/\/doi.org\/10.1016\/j.ejmech.2011.10.031","journal-title":"Eur J Med Chem"},{"key":"11093_CR91","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.bioorg.2017.09.009","volume":"75","author":"AH Abdelazeem","year":"2017","unstructured":"Abdelazeem AH, El-Saadi MT, Said EG et al (2017) Novel diphenylthiazole derivatives with multi-target mechanism: Synthesis, docking study, anticancer and anti-inflammatory activities. Bioorg Chem 75:127\u2013138. https:\/\/doi.org\/10.1016\/j.bioorg.2017.09.009","journal-title":"Bioorg Chem"},{"key":"11093_CR92","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.ejmech.2018.01.061","volume":"146","author":"B Qi","year":"2018","unstructured":"Qi B, Yang Y, He H et al (2018) Identification of novel N1-(2-aryl-1, 3-thiazolidin-4-one)-N3-aryl ureas showing potent multi-tyrosine kinase inhibitory activities. Eur J Med Chem 146:368\u2013380. https:\/\/doi.org\/10.1016\/j.ejmech.2018.01.061","journal-title":"Eur J Med Chem"},{"key":"11093_CR93","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ejmech.2018.11.057","volume":"163","author":"B Qi","year":"2019","unstructured":"Qi B, Yang Y, Gong G et al (2019) Discovery of N1-(4-((7-(3-(4-ethylpiperazin-1-yl)propoxy)-6-methoxyquinolin-4-yl)oxy)-3,5-difluorophenyl)-N3-(2-(2,6-difluorophenyl)-4-oxothiazolidin-3-yl)urea as a multi-tyrosine kinase inhibitor for drug-sensitive and drug-resistant cancers treatment. Eur J Med Chem 163:10\u201327. https:\/\/doi.org\/10.1016\/j.ejmech.2018.11.057","journal-title":"Eur J Med Chem"},{"key":"11093_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2019.111780","volume":"185","author":"AM Shawky","year":"2020","unstructured":"Shawky AM, Abourehab MAS, Abdalla AN, Gouda AM (2020) Optimization of pyrrolizine-based Schiff bases with 4-thiazolidinone motif: Design, synthesis and investigation of cytotoxicity and anti-inflammatory potency. Eur J Med Chem 185:111780. https:\/\/doi.org\/10.1016\/j.ejmech.2019.111780","journal-title":"Eur J Med Chem"},{"key":"11093_CR95","doi-asserted-by":"publisher","first-page":"6069","DOI":"10.1016\/j.bmc.2011.08.038","volume":"19","author":"Y Luo","year":"2011","unstructured":"Luo Y, Li Y, Qiu K-M et al (2011) Metronidazole acid acyl sulfonamide: a novel class of anticancer agents and potential EGFR tyrosine kinase inhibitors. Bioorg Med Chem 19:6069\u20136076. https:\/\/doi.org\/10.1016\/j.bmc.2011.08.038","journal-title":"Bioorg Med Chem"},{"key":"11093_CR96","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1517\/14728222.2011.648617","volume":"16","author":"P Seshacharyulu","year":"2012","unstructured":"Seshacharyulu P, Ponnusamy MP, Haridas D et al (2012) Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets 16:15. https:\/\/doi.org\/10.1517\/14728222.2011.648617","journal-title":"Expert Opin Ther Targets"},{"key":"11093_CR97","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.bmc.2009.10.051","volume":"18","author":"P-C Lv","year":"2010","unstructured":"Lv P-C, Zhou C-F, Chen J et al (2010) Design, synthesis and biological evaluation of thiazolidinone derivatives as potential EGFR and HER-2 kinase inhibitors. Bioorg Med Chem 18:314\u2013319. https:\/\/doi.org\/10.1016\/j.bmc.2009.10.051","journal-title":"Bioorg Med Chem"},{"key":"11093_CR98","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1016\/j.bmc.2012.01.051","volume":"20","author":"K-M Qiu","year":"2012","unstructured":"Qiu K-M, Wang H-H, Wang L-M et al (2012) Design, synthesis and biological evaluation of pyrazolyl-thiazolinone derivatives as potential EGFR and HER-2 kinase inhibitors. Bioorg Med Chem 20:2010\u20132018. https:\/\/doi.org\/10.1016\/j.bmc.2012.01.051","journal-title":"Bioorg Med Chem"},{"key":"11093_CR99","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/S1470-2045(02)00680-0","volume":"3","author":"TA Chan","year":"2002","unstructured":"Chan TA (2002) Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer chemoprevention. Lancet Oncol 3:166\u2013174. https:\/\/doi.org\/10.1016\/S1470-2045(02)00680-0","journal-title":"Lancet Oncol"},{"key":"11093_CR100","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1093\/jnci\/94.4.252","volume":"94","author":"MJ Thun","year":"2002","unstructured":"Thun MJ, Jane Henley S, Patrono C (2002) Nonsteroidal anti-inflammatory drugs as anticancer agents: Mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94:252\u2013266. https:\/\/doi.org\/10.1093\/jnci\/94.4.252","journal-title":"J Natl Cancer Inst"},{"key":"11093_CR101","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S1470-2045(03)01220-8","volume":"4","author":"G Gasparini","year":"2003","unstructured":"Gasparini G, Longo R, Sarmiento R, Morabito A (2003) Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents? Lancet Oncol 4:605\u2013615. https:\/\/doi.org\/10.1016\/S1470-2045(03)01220-8","journal-title":"Lancet Oncol"},{"key":"11093_CR102","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.3390\/ph15121471","volume":"15","author":"N Mohsin","year":"2022","unstructured":"Mohsin N, ul A, Aslam S, Ahmad M, et al (2022) Cyclooxygenase-2 (COX-2) as a target of anticancer agents: a review of novel synthesized scaffolds having anticancer and COX-2 inhibitory potentialities. Pharmaceuticals 15:1471. https:\/\/doi.org\/10.3390\/ph15121471","journal-title":"Pharmaceuticals"},{"key":"11093_CR103","doi-asserted-by":"publisher","unstructured":"Mazhar D, Gillmore R, Waxman J (2005) COX and cancer. QJM: An International Journal of Medicine 98:711\u2013718. https:\/\/doi.org\/10.1093\/qjmed\/hci119","DOI":"10.1093\/qjmed\/hci119"},{"key":"11093_CR104","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1517\/17460441.2014.883377","volume":"9","author":"M Vosooghi","year":"2014","unstructured":"Vosooghi M, Amini M (2014) The discovery and development of cyclooxygenase-2 inhibitors as potential anticancer therapies. Expert Opin Drug Discov 9:255\u2013267. https:\/\/doi.org\/10.1517\/17460441.2014.883377","journal-title":"Expert Opin Drug Discov"},{"key":"11093_CR105","first-page":"625","volume":"62","author":"KM Leahy","year":"2002","unstructured":"Leahy KM, Ornberg RL, Wang Y et al (2002) Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Can Res 62:625\u2013631","journal-title":"Can Res"},{"key":"11093_CR106","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1124\/jpet.104.080564","volume":"314","author":"B Rigas","year":"2005","unstructured":"Rigas B, Kashfi K (2005) Cancer prevention: a new era beyond cyclooxygenase-2. J Pharmacol Exp Ther 314:1\u20138. https:\/\/doi.org\/10.1124\/jpet.104.080564","journal-title":"J Pharmacol Exp Ther"},{"key":"11093_CR107","doi-asserted-by":"publisher","first-page":"599","DOI":"10.2174\/138955707780859431","volume":"7","author":"FH Sarkar","year":"2007","unstructured":"Sarkar FH, Adsule S, Li Y, Padhye S (2007) Back to the future: COX-2 inhibitors for chemoprevention and cancer therapy. Mini-Rev Med Chem 7:599\u2013608. https:\/\/doi.org\/10.2174\/138955707780859431","journal-title":"Mini-Rev Med Chem"},{"key":"11093_CR108","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.bioorg.2014.10.001","volume":"57","author":"AH Abdelazeem","year":"2014","unstructured":"Abdelazeem AH, Gouda AM, Omar HA, Tolba MF (2014) Design, synthesis and biological evaluation of novel diphenylthiazole-based cyclooxygenase inhibitors as potential anticancer agents. Bioorg Chem 57:132\u2013141. https:\/\/doi.org\/10.1016\/j.bioorg.2014.10.001","journal-title":"Bioorg Chem"},{"key":"11093_CR109","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.3390\/ijms18071414","volume":"18","author":"T Eckschlager","year":"2017","unstructured":"Eckschlager T, Plch J, Stiborova M, Hrabeta J (2017) Histone deacetylase inhibitors as anticancer drugs. Int J Mol Sci 18:1414. https:\/\/doi.org\/10.3390\/ijms18071414","journal-title":"Int J Mol Sci"},{"key":"11093_CR110","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmcr.2022.100058","volume":"5","author":"BW Matore","year":"2022","unstructured":"Matore BW, Banjare P, Guria T et al (2022) Oxadiazole derivatives: Histone deacetylase inhibitors in anticancer therapy and drug discovery. Eur J Med Chem Rep 5:100058. https:\/\/doi.org\/10.1016\/j.ejmcr.2022.100058","journal-title":"Eur J Med Chem Rep"},{"key":"11093_CR111","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1016\/j.bmc.2016.02.005","volume":"24","author":"R Liu","year":"2016","unstructured":"Liu R, Wang J, Tang W, Fang H (2016) Design and synthesis of a new generation of substituted purine hydroxamate analogs as histone deacetylase inhibitors. Bioorg Med Chem 24:1446\u20131454. https:\/\/doi.org\/10.1016\/j.bmc.2016.02.005","journal-title":"Bioorg Med Chem"},{"key":"11093_CR112","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1007\/s00044-011-9623-3","volume":"21","author":"R Mohan","year":"2012","unstructured":"Mohan R, Sharma AK, Gupta S, Ramaa CS (2012) Design, synthesis, and biological evaluation of novel 2,4-thiazolidinedione derivatives as histone deacetylase inhibitors targeting liver cancer cell line. Med Chem Res 21:1156\u20131165. https:\/\/doi.org\/10.1007\/s00044-011-9623-3","journal-title":"Med Chem Res"},{"key":"11093_CR113","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1159\/000111106","volume":"72","author":"T Rikimaru","year":"2007","unstructured":"Rikimaru T, Taketomi A, Yamashita Y et al (2007) Clinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinoma. Oncology 72:69\u201374. https:\/\/doi.org\/10.1159\/000111106","journal-title":"Oncology"},{"key":"11093_CR114","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.canlet.2008.03.037","volume":"269","author":"JS Carew","year":"2008","unstructured":"Carew JS, Giles FJ, Nawrocki ST (2008) Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett 269:7\u201317. https:\/\/doi.org\/10.1016\/j.canlet.2008.03.037","journal-title":"Cancer Lett"},{"key":"11093_CR115","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1002\/ijc.10699","volume":"103","author":"Y Yamashita","year":"2003","unstructured":"Yamashita Y, Shimada M, Harimoto N et al (2003) Histone deacetylase inhibitor trichostatin A induces cell-cycle arrest\/apoptosis and hepatocyte differentiation in human hepatoma cells. Int J Cancer 103:572\u2013576. https:\/\/doi.org\/10.1002\/ijc.10699","journal-title":"Int J Cancer"},{"key":"11093_CR116","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2019.103522","volume":"95","author":"K Tilekar","year":"2020","unstructured":"Tilekar K, Upadhyay N, J\u00e4nsch N et al (2020) Discovery of 5-naphthylidene-2,4-thiazolidinedione derivatives as selective HDAC8 inhibitors and evaluation of their cytotoxic effects in leukemic cell lines. Bioorg Chem 95:103522. https:\/\/doi.org\/10.1016\/j.bioorg.2019.103522","journal-title":"Bioorg Chem"},{"key":"11093_CR117","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.ejmech.2012.02.044","volume":"51","author":"S Salamone","year":"2012","unstructured":"Salamone S, Colin C, Grillier-Vuissoz I et al (2012) Synthesis of new troglitazone derivatives: Anti-proliferative activity in breast cancer cell lines and preliminary toxicological study. Eur J Med Chem 51:206\u2013215. https:\/\/doi.org\/10.1016\/j.ejmech.2012.02.044","journal-title":"Eur J Med Chem"},{"key":"11093_CR118","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2020.127561","volume":"30","author":"H Joshi","year":"2020","unstructured":"Joshi H, Patil V, Tilekar K et al (2020) Benzylidene thiazolidinediones: Synthesis, in vitro investigations of antiproliferative mechanisms and in vivo efficacy determination in combination with Imatinib. Bioorg Med Chem Lett 30:127561. https:\/\/doi.org\/10.1016\/j.bmcl.2020.127561","journal-title":"Bioorg Med Chem Lett"},{"key":"11093_CR119","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2020.105512","volume":"154","author":"K Tilekar","year":"2020","unstructured":"Tilekar K, Upadhyay N, Schweipert M et al (2020) Permuted 2,4-thiazolidinedione (TZD) analogs as GLUT inhibitors and their in-vitro evaluation in leukemic cells. Eur J Pharm Sci 154:105512. https:\/\/doi.org\/10.1016\/j.ejps.2020.105512","journal-title":"Eur J Pharm Sci"},{"key":"11093_CR120","doi-asserted-by":"publisher","first-page":"7613","DOI":"10.1039\/C8CC03399D","volume":"54","author":"S Terracciano","year":"2018","unstructured":"Terracciano S, Lauro G, Russo A et al (2018) Discovery and synthesis of the first selective BAG domain modulator of BAG3 as an attractive candidate for the development of a new class of chemotherapeutics. Chem Commun 54:7613\u20137616. https:\/\/doi.org\/10.1039\/C8CC03399D","journal-title":"Chem Commun"},{"key":"11093_CR121","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.semcdb.2017.08.049","volume":"78","author":"M De Marco","year":"2018","unstructured":"De Marco M, Basile A, Iorio V et al (2018) Role of BAG3 in cancer progression: A therapeutic opportunity. Semin Cell Dev Biol 78:85\u201392. https:\/\/doi.org\/10.1016\/j.semcdb.2017.08.049","journal-title":"Semin Cell Dev Biol"},{"key":"11093_CR122","doi-asserted-by":"publisher","DOI":"10.3390\/MOLECULES27030665","author":"D Ruggiero","year":"2022","unstructured":"Ruggiero D, Terracciano S, Lauro G et al (2022) Structural refinement of 2,4-thiazolidinedione derivatives as new anticancer agents able to modulate the BAG3 protein. Molecules. https:\/\/doi.org\/10.3390\/MOLECULES27030665","journal-title":"Molecules"},{"key":"11093_CR123","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.ejmech.2013.02.030","volume":"63","author":"R Romagnoli","year":"2013","unstructured":"Romagnoli R, Baraldi PG, Salvador MK et al (2013) Anticancer activity of novel hybrid molecules containing 5-benzylidene thiazolidine-2,4-dione. Eur J Med Chem 63:544\u2013557. https:\/\/doi.org\/10.1016\/j.ejmech.2013.02.030","journal-title":"Eur J Med Chem"},{"key":"11093_CR124","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2020.103569","volume":"96","author":"H El-Kashef","year":"2020","unstructured":"El-Kashef H, Badr G, Abo El-Maali N et al (2020) Synthesis of a novel series of (Z)-3,5-disubstituted thiazolidine-2,4-diones as promising anti-breast cancer agents. Bioorg Chem 96:103569. https:\/\/doi.org\/10.1016\/j.bioorg.2020.103569","journal-title":"Bioorg Chem"},{"key":"11093_CR125","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1007\/s00044-013-0902-z","volume":"23","author":"MJBDM R\u00eago","year":"2014","unstructured":"R\u00eago MJBDM, Galdino-Pitta MR, Pereira DTM et al (2014) Synthesis, in vitro anticancer activity and in silico study of new disubstituted thiazolidinedione derivatives. Med Chem Res 23:3220\u20133226. https:\/\/doi.org\/10.1007\/s00044-013-0902-z","journal-title":"Med Chem Res"},{"key":"11093_CR126","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.ejmech.2017.02.031","volume":"129","author":"N MohdJ","year":"2017","unstructured":"MohdJ N, Alam MdJ, Ahmad S et al (2017) Therapeutic journey of 2,4-thiazolidinediones as a versatile scaffold: An insight into structure activity relationship. Eur J Med Chem 129:218\u2013250. https:\/\/doi.org\/10.1016\/j.ejmech.2017.02.031","journal-title":"Eur J Med Chem"},{"key":"11093_CR127","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1038\/nature08622","volume":"462","author":"W Zhou","year":"2009","unstructured":"Zhou W, Ercan D, Chen L et al (2009) Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 462:1070\u20131074. https:\/\/doi.org\/10.1038\/nature08622","journal-title":"Nature"},{"key":"11093_CR128","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.ejmech.2016.08.029","volume":"124","author":"P Sharma","year":"2016","unstructured":"Sharma P, Srinivasa Reddy T, Thummuri D et al (2016) Synthesis and biological evaluation of new benzimidazole-thiazolidinedione hybrids as potential cytotoxic and apoptosis inducing agents. Eur J Med Chem 124:608\u2013621. https:\/\/doi.org\/10.1016\/j.ejmech.2016.08.029","journal-title":"Eur J Med Chem"},{"key":"11093_CR129","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.ejmech.2011.11.006","volume":"47","author":"RF George","year":"2012","unstructured":"George RF (2012) Stereoselective synthesis and QSAR study of cytotoxic 2-(4-oxo-thiazolidin-2-ylidene)-2-cyano-N-arylacetamides. Eur J Med Chem 47:377\u2013386. https:\/\/doi.org\/10.1016\/j.ejmech.2011.11.006","journal-title":"Eur J Med Chem"},{"key":"11093_CR130","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115824","volume":"261","author":"F Budassi","year":"2023","unstructured":"Budassi F, Marchioro C, Canton M et al (2023) Design, synthesis and biological evaluation of novel 2,4-thiazolidinedione derivatives able to target the human BAG3 protein. Eur J Med Chem 261:115824. https:\/\/doi.org\/10.1016\/j.ejmech.2023.115824","journal-title":"Eur J Med Chem"},{"key":"11093_CR131","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2020.103934","volume":"100","author":"N Upadhyay","year":"2020","unstructured":"Upadhyay N, Tilekar K, J\u00e4nsch N et al (2020) Discovery of novel N-substituted thiazolidinediones (TZDs) as HDAC8 inhibitors: in-silico studies, synthesis, and biological evaluation. Bioorg Chem 100:103934. https:\/\/doi.org\/10.1016\/j.bioorg.2020.103934","journal-title":"Bioorg Chem"},{"key":"11093_CR132","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e24005","volume":"10","author":"IH Eissa","year":"2024","unstructured":"Eissa IH, Elkady H, Rashed M et al (2024) Discovery of new thiazolidine-2,4-dione derivatives as potential VEGFR-2 inhibitors: In vitro and in silico studies. Heliyon 10:e24005. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e24005","journal-title":"Heliyon"},{"key":"11093_CR133","doi-asserted-by":"publisher","first-page":"3387","DOI":"10.3390\/molecules29143387","volume":"29","author":"M Garberov\u00e1","year":"2024","unstructured":"Garberov\u00e1 M, Kudli\u010dkov\u00e1 Z, Michalkov\u00e1 R et al (2024) Design, synthesis, and characterization of novel thiazolidine-2,4-dione-acridine hybrids as antitumor agents. Molecules 29:3387. https:\/\/doi.org\/10.3390\/molecules29143387","journal-title":"Molecules"},{"key":"11093_CR134","doi-asserted-by":"publisher","first-page":"2000071","DOI":"10.1002\/ardp.202000071","volume":"353","author":"MA Iqbal","year":"2020","unstructured":"Iqbal MA, Husain A, Alam O et al (2020) Design, synthesis, and biological evaluation of imidazopyridine-linked thiazolidinone as potential anticancer agents. Arch Pharm 353:2000071. https:\/\/doi.org\/10.1002\/ardp.202000071","journal-title":"Arch Pharm"},{"key":"11093_CR135","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s43556-024-00204-z","volume":"5","author":"Y Dhas","year":"2024","unstructured":"Dhas Y, Biswas N, M.R. D, et al (2024) Repurposing metabolic regulators: antidiabetic drugs as anticancer agents. Mol Biomed 5:40. https:\/\/doi.org\/10.1186\/s43556-024-00204-z","journal-title":"Mol Biomed"},{"key":"11093_CR136","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1200\/JGO.2019.5.suppl.83","volume":"5","author":"R Moghareabed","year":"2019","unstructured":"Moghareabed R, Hemati S, Akhavan A et al (2019) Randomized phase II clinical trial of pioglitazone plus chemotherapy versus chemotherapy alone in patients with metastatic breast cancer. JGO 5:83\u201383. https:\/\/doi.org\/10.1200\/JGO.2019.5.suppl.83","journal-title":"JGO"},{"key":"11093_CR137","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1158\/1940-6207.CAPR-19-0006","volume":"12","author":"RL Keith","year":"2019","unstructured":"Keith RL, Blatchford PJ, Merrick DT et al (2019) A randomized phase II trial of pioglitazone for lung cancer chemoprevention in high-risk current and former smokers. Cancer Prev Res 12:721\u2013730. https:\/\/doi.org\/10.1158\/1940-6207.CAPR-19-0006","journal-title":"Cancer Prev Res"},{"key":"11093_CR138","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1210\/jc.2017-02533","volume":"103","author":"TJ Giordano","year":"2018","unstructured":"Giordano TJ, Haugen BR, Sherman SI et al (2018) Pioglitazone therapy of PAX8-PPAR\u03b3 fusion protein thyroid carcinoma. J Clin Endocrinol Metab 103:1277\u20131281. https:\/\/doi.org\/10.1210\/jc.2017-02533","journal-title":"J Clin Endocrinol Metab"},{"key":"11093_CR139","unstructured":"National Cancer Institute (NCI) (2022) A Phase IIa Cancer Prevention Trial of the PPAR Gamma Agonist Pioglitazone in Oral Leukoplakia. clinicaltrials.gov"},{"key":"11093_CR140","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.2337\/dc07-2308","volume":"31","author":"M Monami","year":"2008","unstructured":"Monami M, Lamanna C, Marchionni N, Mannucci E (2008) Rosiglitazone and risk of cancer: A meta-analysis of randomized clinical trials. Diabetes Care 31:1455\u20131460. https:\/\/doi.org\/10.2337\/dc07-2308","journal-title":"Diabetes Care"},{"key":"11093_CR141","unstructured":"Demetri G (2017) Phase II Clinical Trial of TROGLITAZONE, a Ligand for the Peroxisome Proliferator-Activated Receptor Gamma (PPAR), as Antineoplastic Differentiation Therapy for Patients with Malignant Liposarcoma. clinicaltrials.gov"},{"key":"11093_CR142","unstructured":"Cancer drug and uses, World Intellectual Property Organization, WO2014108571A2, 2014."},{"key":"11093_CR143","unstructured":"Application of PPAR-\u03b3 and its ligands in the preparation of drugs for treating ophthalmic diseases, China, CN103893177A, 2014."},{"key":"11093_CR144","unstructured":"Compositions for treating cancer and methods for making the same, World Intellectual Property Organization, WO2013188763A1, 2013."},{"key":"11093_CR145","unstructured":"Myc modulators and uses thereof, United States, US10017520B2, 2018."},{"key":"11093_CR146","unstructured":"Substituted phenoxy thiazolidinediones as estrogen related receptor-\u00e1 modulators, United States, US8344009B2, 2013."},{"key":"11093_CR147","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1634\/theoncologist.2012-0302","volume":"18","author":"C Bosetti","year":"2013","unstructured":"Bosetti C, Rosato V, Buniato D et al (2013) Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis. Oncologist 18:148\u2013156. https:\/\/doi.org\/10.1634\/theoncologist.2012-0302","journal-title":"Oncologist"},{"key":"11093_CR148","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1517\/14740330802597821","volume":"8","author":"C Rizos","year":"2009","unstructured":"Rizos C, Elisaf M, Mikhailidis D, Liberopoulos E (2009) How safe is the use of thiazolidinediones in clinical practice? Expert Opin Drug Saf 8:15\u201332. https:\/\/doi.org\/10.1517\/14740330802597821","journal-title":"Expert Opin Drug Saf"},{"key":"11093_CR149","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s11892-019-1270-y","volume":"19","author":"HE Lebovitz","year":"2019","unstructured":"Lebovitz HE (2019) Thiazolidinediones: The forgotten diabetes medications. Curr DiabRep 19:151. https:\/\/doi.org\/10.1007\/s11892-019-1270-y","journal-title":"Curr DiabRep"},{"key":"11093_CR150","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1002\/pds.1804","volume":"18","author":"JS Floyd","year":"2009","unstructured":"Floyd JS, Barbehenn E, Lurie P, Wolfe SM (2009) Case series of liver failure associated with rosiglitazone and pioglitazone. Pharmacoepidemiol Drug Saf 18:1238\u20131243. https:\/\/doi.org\/10.1002\/pds.1804","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"11093_CR151","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/646423","volume":"2015","author":"S Horita","year":"2015","unstructured":"Horita S, Nakamura M, Satoh N et al (2015) Thiazolidinediones and Edema: recent advances in the pathogenesis of thiazolidinediones-induced renal sodium retention. PPAR Res 2015:646423. https:\/\/doi.org\/10.1155\/2015\/646423","journal-title":"PPAR Res"},{"key":"11093_CR152","doi-asserted-by":"publisher","first-page":"102","DOI":"10.7570\/jomes.2017.26.2.102","volume":"26","author":"KD Ko","year":"2017","unstructured":"Ko KD, Kim KK, Lee KR (2017) Does weight gain associated with thiazolidinedione use negatively affect cardiometabolic health? J Obesity Metabolic Syndrome 26:102\u2013106. https:\/\/doi.org\/10.7570\/jomes.2017.26.2.102","journal-title":"J Obesity Metabolic Syndrome"},{"key":"11093_CR153","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2013.00011","author":"MT Bazelier","year":"2013","unstructured":"Bazelier MT (2013) Risk of fracture with thiazolidinediones: an individual patient data meta-analysis. Front Endocrinol. https:\/\/doi.org\/10.3389\/fendo.2013.00011","journal-title":"Front Endocrinol"},{"key":"11093_CR154","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1007\/s00223-012-9591-8","volume":"90","author":"MT Bazelier","year":"2012","unstructured":"Bazelier MT, Vestergaard P, Gallagher AM et al (2012) Risk of fracture with thiazolidinediones: disease or drugs? Calcif Tissue Int 90:450\u2013457. https:\/\/doi.org\/10.1007\/s00223-012-9591-8","journal-title":"Calcif Tissue Int"},{"key":"11093_CR155","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1002\/dmrr.252","volume":"18","author":"HE Lebovitz","year":"2002","unstructured":"Lebovitz HE (2002) Differentiating members of the thiazolidinedione class: a focus on safety. Diabetes Metab Res Rev 18:S23\u2013S29. https:\/\/doi.org\/10.1002\/dmrr.252","journal-title":"Diabetes Metab Res Rev"},{"key":"11093_CR156","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1200\/JCO.2006.07.2777","volume":"25","author":"R Govindarajan","year":"2007","unstructured":"Govindarajan R, Ratnasinghe L, Simmons DL et al (2007) Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol 25:1476\u20131481. https:\/\/doi.org\/10.1200\/JCO.2006.07.2777","journal-title":"J Clin Oncol"},{"key":"11093_CR157","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1002\/pds.1352","volume":"16","author":"C Koro","year":"2007","unstructured":"Koro C, Barrett S, Qizilbash N (2007) Cancer risks in thiazolidinedione users compared to other anti-diabetic agents. Pharmacoepidemiol Drug Saf 16:485\u2013492. https:\/\/doi.org\/10.1002\/pds.1352","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"11093_CR158","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2023\/9462176","volume":"2023","author":"B Ansari","year":"2023","unstructured":"Ansari B, Khan H, Jan MS et al (2023) Synthesis, characterization, and pharmacokinetic studies of thiazolidine-2,4-dione derivatives. J Chem 2023:1\u201311. https:\/\/doi.org\/10.1155\/2023\/9462176","journal-title":"J Chem"},{"key":"11093_CR159","doi-asserted-by":"publisher","first-page":"917","DOI":"10.2217\/14622416.8.8.917","volume":"8","author":"CL Aquilante","year":"2007","unstructured":"Aquilante CL (2007) Pharmacogenetics of thiazolidinedione therapy. Pharmacogenomics 8:917\u2013931. https:\/\/doi.org\/10.2217\/14622416.8.8.917","journal-title":"Pharmacogenomics"},{"key":"11093_CR160","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/978-981-16-5123-6_11","volume-title":"Stroke Revisited Diabetes in Stroke","author":"JC Won","year":"2021","unstructured":"Won JC (2021) Thiazolidinediones (TZDs). In: Lee S-H, Kang D-W (eds) Stroke Revisited Diabetes in Stroke. Springer, Singapore, pp 131\u2013141"},{"key":"11093_CR161","doi-asserted-by":"publisher","first-page":"932","DOI":"10.2174\/1381612826666200122124116","volume":"26","author":"LA Biondo","year":"2020","unstructured":"Biondo LA, Teixeira AAS, Ferreira DOS, KC, Neto JCR, (2020) Pharmacological strategies for insulin sensitivity in obesity and cancer: thiazolidinediones and metformin. Curr Pharm Des 26:932\u2013945. https:\/\/doi.org\/10.2174\/1381612826666200122124116","journal-title":"Curr Pharm Des"},{"key":"11093_CR162","doi-asserted-by":"publisher","unstructured":"Gyampoh S (2024) Virtual Screening of 5-Benzylthiazolidine-2,4-Dione Derivatives in Search of Potent Ppar-Gamma Agonist. Available at SSRN: https:\/\/ssrn.com\/abstract=4817066. https:\/\/doi.org\/10.2139\/ssrn.4817066","DOI":"10.2139\/ssrn.4817066"},{"key":"11093_CR163","doi-asserted-by":"publisher","DOI":"10.1002\/slct.202400123","volume":"9","author":"S Ravi","year":"2024","unstructured":"Ravi S, Gaddamedi S, Gopal Agrawal H et al (2024) Design, synthesis, biological evaluation, and molecular docking studies of N3-Functionalized TZD-indole conjugates as potential anticancer agents. ChemistrySelect 9:e202400123. https:\/\/doi.org\/10.1002\/slct.202400123","journal-title":"ChemistrySelect"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-024-11093-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-024-11093-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-024-11093-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T12:29:32Z","timestamp":1763728172000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11030-024-11093-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,3]]},"references-count":163,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["11093"],"URL":"https:\/\/doi.org\/10.1007\/s11030-024-11093-3","relation":{},"ISSN":["1381-1991","1573-501X"],"issn-type":[{"value":"1381-1991","type":"print"},{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,3]]},"assertion":[{"value":"8 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing commercial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}]}}